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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer worldwide. The incidence and mortality of HCC
have increased three-fold in the United States over the
past few years and the majority of patients present with
advanced disease. Bavituximab is a novel chimeric IgG1
monoclonal antibody that selectively blocks phosphatidyl-
serine (PS), a membrane phospholipid exposed on the
tumor vasculature, tumor cells and tumor-derived exo-
somes. PS is tightly segregated to the inner leaflet of the
plasma membrane, but becomes externalized on the outer
surface of dying cells and vascular endothelium in
response to oxidative stress, hypoxia, chemotherapy, radia-
tion and other physiological stressors in the tumor
microenvironment.
Pre-clinical data demonstrate that Sorafenib increases PS
exposure on vascular endothelium and HCC tumor cells.
The combination of Sorafenib with a murine Bavituximab
analogue potentially inhibited HCC tumor xenograft
growth and induced an immunostimulatory macrophage
phenotype. Following the preclinical efforts, a Phase I
study was completed concluding that Sorafenib (400 mg)
and Bavituximab (3 mg/kg) can be safely given in patients
with advanced HCC.
Methods
Patients in an ongoing open-label, single-center Phase II
therapeutic study of Sorafenib and Bavituximab, patients
consented to undergo two image guided core needle biop-
sies of a single site of HCC obtained at the time of diagno-
sis and following one cycle of treatment with Bavituximab
and Sorafenib. Treatment cycles consisting of four weekly
doses of Bavituximab (3 mg/kg I.V.) and four weeks of
Sorafenib (400 mg P.O. BID) were repeated until progres-
sion or toxicity. Histologic analysis of immune and mye-
loid infiltrates (specifically helper and cytotoxic T cells,
and macrophages) in tumor tissues was performed.
Results
In 2 (33%) of the analyzed 6 patients, treatment of HCC
patients with Bavituximab and Sorafenib increased infil-
tration of CD4+ (T-helper cells), and CD8+ (cytotoxic
T-cells) ≥ 2-fold, with a corresponding decrease in
FoxP3+ (regulatory T-cells) in the tumor microenviron-
ment one cycle post- treatment as compared to baseline.
Increased infiltration of tumor associated macrophages ≥
2-fold was also observed post treatment in these two
individuals.
Preliminary conclusions
Immunohistochemical evaluation of HCC tumor tissues
post combination treatment indicated an increase of
immune infiltrates; raising the potential of a clinically
meaningful anti-tumor immune response. The prevalence
of such immune cells within the tumor microenviron-
ment correlates with the pre-clinical experience with
Bavituximab in combination with Sorafenib in murine
models of HCC.
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